Evidence map›Paper›PMID 21423586›Full record

ArticlePLoS medicine2011

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Edward C Jones-López, Irene Ayakaka, Jonathan Levin, Nancy Reilly, Francis Mumbowa, Scott Dryden-Peterson, Grace Nyakoojo, Kevin Fennelly, Beth Temple, Susan Nakubulwa and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018
    Pooled it
  3. Pooled it
  4. A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 4 countries.

Edward C Jones-LópezSection of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston University Medical School, Boston, Massachusetts, USA. edward.jones@bmc.org
Irene Ayakaka
Jonathan Levin
Nancy Reilly
Francis Mumbowa
Scott Dryden-Peterson
Grace Nyakoojo
Kevin Fennelly
Beth Temple
Susan Nakubulwa
Moses L Joloba
Alphonse Okwera
Kathleen D Eisenach
Ruth McNerney
Alison M Elliott
Jerrold J Ellner
Peter G Smith
Roy D Mugerwa
Makerere University · UGMUJHU Research Collaboration · UGUganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GBBoston Medical Center · USBoston University · USHarvard University · USRutgers, The State University of New Jersey · USUniversity of Arkansas for Medical Sciences · USUniversity of Florida · US

Funding

Medical Research Council G0700837Wellcome TrustWellcome Trust 063410/ABC/00/Z
6 · The paper itself

Abstract

backgroundEach year, 10%-20% of patients with tuberculosis (TB) in low- and middle-income countries present with previously treated TB and are empirically started on a World Health Organization (WHO)-recommended standardized retreatment regimen. The effectiveness of this retreatment regimen has not been systematically evaluated. METHODS AND

findingsFrom July 2003 to January 2007, we enrolled smear-positive, pulmonary TB patients into a prospective cohort to study treatment outcomes and mortality during and after treatment with the standardized retreatment regimen. Median time of follow-up was 21 months (interquartile range 12-33 months). A total of 29/148 (20%) HIV-uninfected and 37/140 (26%) HIV-infected patients had an unsuccessful treatment outcome. In a multiple logistic regression analysis to adjust for confounding, factors associated with an unsuccessful treatment outcome were poor adherence (adjusted odds ratio [aOR] associated with missing half or more of scheduled doses 2.39; 95% confidence interval (CI) 1.10-5.22), HIV infection (2.16; 1.01-4.61), age (aOR for 10-year increase 1.59; 1.13-2.25), and duration of TB symptoms (aOR for 1-month increase 1.12; 1.04-1.20). All patients with multidrug-resistant TB had an unsuccessful treatment outcome. HIV-infected individuals were more likely to die than HIV-uninfected individuals (p<0.0001). Multidrug-resistant TB at enrollment was the only common risk factor for death during follow-up for both HIV-infected (adjusted hazard ratio [aHR] 17.9; 6.0-53.4) and HIV-uninfected (14.7; 4.1-52.2) individuals. Other risk factors for death during follow-up among HIV-infected patients were CD4<50 cells/ml and no antiretroviral treatment (aHR 7.4, compared to patients with CD4≥200; 3.0-18.8) and Karnofsky score <70 (2.1; 1.1-4.1); and among HIV-uninfected patients were poor adherence (missing half or more of doses) (3.5; 1.1-10.6) and duration of TB symptoms (aHR for a 1-month increase 1.9; 1.0-3.5).

conclusionsThe recommended regimen for retreatment TB in Uganda yields an unacceptable proportion of unsuccessful outcomes. There is a need to evaluate new treatment strategies in these patients.

Indexed as

AdultAge FactorsAntitubercular AgentsCohort StudiesDrug Resistance, BacterialFemaleHIV InfectionsHumansLogistic ModelsMalePractice Guidelines as TopicPrevalenceProspective StudiesRetreatmentTreatment FailureTreatment OutcomeAntitubercular Agents

Identifiers

PMID21423586
PMCPMC3058098
OpenAlexW2041063042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.